Guillaume Hagège serves as Head of Corporate and Scientific Strategy and is a member of DBV’s Executive Committee. He oversees DBV’s scientific and corporate strategy and is in charge of the identification of key development opportunities for DBV and its EPIT platform.
Mr Hagège has ten years of experience in the field of pharmaceutical industry and biotechnology. He joined DBV in September 2018 as Vice President Strategy. Prior to DBV, he was Project Leader at the Boston Consulting Group (BCG), where he spent 6 years as core member of the Healthcare practice, working with various large pharmaceutical companies, biotech companies, global health organizations or investors on all activities along the value chain.
Mr Hagège holds a Master in Strategic Management from HEC Paris and a Master of Sciences from both Imperial College London and ISAE Supaero.